<p>Inflammatory skin diseases and skin cancers are usually accompanied by metabolic comorbidities or altered metabolic status. Metabolomic analysis indicates that patients with inflammatory skin diseases and skin cancers exhibit altered metabolites, including glycans, lipids, and amino acids. This suggests that metabolic reprogramming may play a pivotal role in the pathogenesis of these skin diseases. The solute carrier (SLC) superfamily is responsible for the transport of a range of metabolites, which may serve as crucial intermediate links in the metabolic reprogramming of diseases. Nevertheless, research on the SLC superfamily in skin diseases remains limited, and the development of its drug targets is even more scarce. Therefore, this review is devoted to elucidating our current understanding of the role of the SLC family in the pathogenesis of inflammatory skin diseases and skin cancers, with a particular emphasis on its role in metabolic reprogramming. In doing so, we aim to provide a reference point for the subsequent development of drug targets for the SLC family in skin diseases.</p>